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ABSTRACT
The epithelial-mesenchymal transition (EMT) is implicated in tumorigenesis 
and cancer progression, and canonical Wnt signaling tightly controls Snail, a key 
transcriptional repressor of EMT. While the suppression of canonical Wnt signaling and 
EMT comprises an attractive therapeutic strategy, molecular targets for small molecules 
reverting Wnt and EMT have not been widely studied. Meanwhile, the anti-helminthic 
niclosamide has been identified as a potent inhibitor of many oncogenic signaling 
pathways although its molecular targets have not yet been clearly identified. In this 
study, we show that niclosamide directly targets Axin-GSK3 interaction, at least in part, 
resulting in suppression of Wnt/Snail-mediated EMT. In vitro and in vivo, disruption of 
Axin-GSK3 complex by niclosamide induces mesenchymal to epithelial reversion at nM 
concentrations, accompanied with suppression of the tumorigenic potential of colon 
cancer. Niclosamide treatment successfully attenuates Snail abundance while increasing 
E-cadherin abundance in xenograft tumor. Notably, oral administration of niclosamide 
significantly suppressed adenoma formation in an APC-MIN mice model, indicating that 
niclosamide is an effective therapeutic for familial adenomatosis polyposis (FAP) patients. 
In this study, we identified a novel target to control the canonical Wnt pathway and Snail-
mediated EMT program, and discovered a repositioned therapeutics for FAP patients.
INTRODUCTION
As the EMT comprises a biological mechanism that 
induces invasive and stemness properties with therapeutic 
resistance in human cancer [1], reverting EMT with small 
molecule inhibitors is an attractive therapeutic strategy for 
cancer [2]. It has been found that salinomycin can effectively 
revert EMT, resulting in significant suppression of cancer 
stemness by 100-fold relative to paclitaxel and of metastatic 
potential of breast cancer cells in vivo [2]. Although 
salinomycin is limited for human, this finding suggests a 
novel strategy for regulating EMT in human cancer.
The transcription factor Snail triggers EMT in 
human cancer by suppressing epithelial genes [3]. 
Previous studies reveal that major oncogenic pathways, 
such as canonical Wnt signaling, p53 tumor suppressor, 
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and bacterial carcinogen CagA protein of H. pyroli, 
modulate Snail activities via post-transcriptional and post-
translational mechanisms [4-6]. Importantly, β-catenin 
and Snail transcriptional machinery are phosphorylated 
and degraded by GSK3, and canonical Wnt signaling 
or CagA inhibits the phosphorylation, consequently 
increasing TCF transcriptional activity and driving the 
Snail-mediated EMT program [4-8]. Axin2, a GSK3 
scaffolding protein, plays a key regulatory function in 
this process by regulating nuclear-cytoplasmic shuttling 
of GSK3, resulting in increased nuclear Snail in cancer 
cells [8, 9]. The GSK3 shuttling function by Axin is also 
required for phosphorylation of the membranous LRP6 Wnt 
co-receptor and subsequent activation of intracellular Wnt 
signaling [10]. These observations indicate that Axin-GSK3 
complex may play an important role in regulating canonical 
Wnt signaling and the Snail-mediated EMT program. 
Conversely, targeted disruption of the Axin-GSK3 complex 
can be a novel mode of action (MoA) in developing a small 
molecule inhibitor targeting Wnt signaling and the Snail-
mediated EMT program for human cancer.
Niclosamide is an FDA-approved anti-helminthic 
drug used worldwide against intestinal cestodes infection for 
nearly 50 years [11]. Since niclosamide was reported as an 
effective agent for human colon cancer in vitro and in vivo 
[12, 13], a large body of recent studies have revealed that 
it can be used for various types of human cancers [14, 15]. 
Based on these observations, we addressed two concerns 
regarding the MoA of niclosamide. First, niclosamide 
induced cancer cell death at μM concentration level in vitro 
while physiological concentration in vivo exhibited nM 
level in plasma and cancer tissue [12, 13], indicating a non-
cytotoxic MoA in vivo. Second, while many targets, such as 
Notch signaling, Dishevelled, S100A4, and Frizzled receptor, 
have been proposed [12-14], the direct target providing the 
MoA of the niclosamide has not yet been clearly identified.
In this study, we found that niclosamide directly disrupts 
the Axin-GSK3 complex, at least in part, resulting in attenuation 
of canonical Wnt activity with reversion of Snail-mediated 
EMT in colon cancer cells. Further, niclosamide attenuates 
TCF/LEF transcriptional activity induced by APC mutants, 
and oral administration of niclosamide significantly suppresses 
adenoma formation in an APC-MIN model, of clinical 
relevance for familial adenomatosis polyposis (FAP) patients. 
Considering the limited treatment options for and clinical 
complications of FAP, our observations suggest a potential 
therapeutic for FAP patients based on a novel target and MoA.
RESULTS
Niclosamide attenuates canonical Wnt activity 
with reversal of Snail-mediated EMT at nM 
levels in colon cancer cells
While earlier studies focused on cell death at μM levels 
in vitro, we hypothesized that niclosamide inhibits the EMT 
process in a physiologically relevant nM concentration [12, 
13]. To examine this hypothesis, we first screened cancer 
cell death with variable concentration in colon cancer 
cells and found that niclosamide induced cell death at μM 
level whereas nM concentrations did not (Figure 1A). We 
then evaluated β-catenin protein abundance and TCF/LEF 
transcriptional activity with reference to physiological 
levels of niclosamide in colon cancer cells. Consistent with 
previous observations [12], niclosamide suppressed β-catenin 
protein abundance and TCF/LEF activity in a dose-dependent 
manner (Figure 1B). Because the canonical Wnt pathway 
directly up-regulates the Snail-mediated EMT program of 
cancer cells [7, 8], we next examined Snail and E-cadherin 
protein abundance. Examining protein abundance of Snail 
and E-cadherin, we found niclosamide treatment suppressed 
Snail abundance while increasing E-cadherin in colon cancer 
cells (Figure 1C). Given the well-known function of Snail as 
an E-cadherin transcriptional repressor [16, 17], nM levels of 
niclosamide were sufficient to increase E-cadherin promoter 
activities (Figure 1D).
As a scaffolding protein of the Wnt pathway [18, 
19], Axin2 shuttles GSK3 to increase membranous LRP6 
phosphorylation/stabilization and to decrease nuclear 
GSK3 activity, activating intracellular signaling of 
Wnt and Snail-mediated EMT [8, 10]. Although earlier 
studies have suggested that Axin is a tumor suppressor, 
recent evidence supports the important role of Axin2 in 
canonical TCF/LEF activity as well as in Snail-mediated 
EMT progression [8, 9, 20]. As a TCF/LEF target gene, 
the Axin2 is highly expressed in colon cancer due to 
loss of APC tumor suppressor function or β-catenin 
mutation [18, 19, 21], and we validated increased Axin2 
abundance in colon cancer cell panels (Supplementary 
Figure 1A). Next, we examined whether Axin2 regulates 
TCF/LEF transcriptional activity and the Snail-mediated 
EMT program in colon cancer cells. Consistent with 
previous observations [9], inducible knock-down of 
Axin2 exhibited suppression of canonical Wnt activity in 
tandem with reversion of Snail-mediated EMT, similarly 
to niclosamide treatment (Supplementary Figure 1B-1E). 
Because Axin2 is required for nuclear and membranous 
GSK-3 dynamics [8-10], we next examined abundance 
of nuclear GSK3 and phosphorylated LRP6. Indeed, 
niclosamide treatment increased nuclear GSK3 whereas 
β-catenin and Snail abundances were suppressed in a 
colon cancer panel (Figure 2). The phosphorylation and 
protein abundance of LPR6, a Wnt co-receptor, were also 
significantly suppressed by niclosamide (Supplementary 
Figure 2). These data support that niclosamide may affect 
Axin function in colon cancer cells.
Niclosamide directly binds to GSK3, disrupting 
the Axin-GSK3 complex
During the Wnt signal transduction, Axin serves as a 
scaffolding protein that directly interacts with GSK3 [22], 
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and Axin1 and Axin2 proteins are functionally equivalent 
in vivo [23]. We validated Axin2 functions as equivalent 
to Axin1 in terms of GSK3 binding and nuclear export 
function based on structural analysis (Supplementary 
Figure 3A) [24]. To determine whether niclosamide can 
inhibit Axin-GSK3 interaction, we subjected the lysate of 
cells expressing full-length Axin2 to immunoprecipitation 
in absence or presence of niclosamide. Indeed, niclosamide 
decreased GSK3 binding to Axin2 in cells and in vitro 
cell lysate samples (Figure 3A & Supplementary Figure 
3B). Previous structural analysis of Axin-GSK3 binding 
indicated that hydrophobic residues on α helix of 
Axin are packed into a hydrophobic groove formed by 
C-terminal loops in GSK3 [24]. Thus, we hypothesized 
that niclosamide can bind to the hydrophobic groove on 
GSK3, inhibiting Axin function. To test this notion, we 
Figure 1: Niclosamide reverses Snail-mediated EMT at nM levels with suppression of canonical Wnt signaling. (A) Cell 
viability of colon cancer cells after treatment of niclosamide for a 48-h period. Cell viability was determined by trypan blue exclusion 
assay from triplicate experiments. (B) Effect of niclosamide on β-catenin abundance (left panels) and TCF/LEF reporter (Topflash) activity 
(right panel) in colon cancer cells transiently transfected with Topflash with Renilla luciferase and treated with different concentrations of 
niclosamide (0, 0.125, 0.25, and 0.5 μM) for 24 h. The reporter activity was determined by measuring the luciferase normalized with Renilla 
from triplicate experiments. (C) Niclosamide suppresses Snail-mediated EMT. The colon cancer cells were treated with niclosamide at 
the indicated concentrations for 24 h, and protein abundance of Snail and E-cadherin was determined by immunoblot analysis. (D) Colon 
cancer cells were transiently transfected with wild type or 3x mutant E-cadherin proximal reporter vector with Renilla control. Cells were 
treated with different concentrations of niclosamide for 24 h. The reporter activity was determined by measuring the luciferase activity 
normalized with Renilla activity from triplicate experiments. Relative reporter activity of wild type E-box compared to 3x E-box mutant 
reporter is presented. Statistical significances compared to control are denoted as *, P < 0.05; **, P < 0.01 by a two-tailed Student’s t-test.
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next designed a cell-free assay system for competitive 
inhibition by niclosamide of recombinant GSK3 
binding to 19-mer FITC-conjugated Axin peptide (AFF 
assay). Interestingly, niclosamide disrupted interaction 
between recombinant GSK3 and synthetic Axin peptide 
in a dose-dependent manner in AFF assay (Figure 3B), 
indicating that niclosamide inhibits Axin-GSK3 binding 
in a cell-free system. We next performed surface plasma 
resonance (SPR) analysis to determine whether there was 
direct binding of niclosamide to GSK3. As shown in the 
sensograms (Figure 3C and Supplementary Figure 3C), 
wild type Axin peptide or niclosamide directly binds to 
GSK3, the equilibrium dissociation constant yielding 
a KD valueof 11.9 μM and 34.5 μM in SPR analysis, 
respectively. Mutant Axin peptide having mutations on 
hydrophobic residues at GSK3 protein immobilized on 
the sensor surface did not bind up to 20μM. In general, 
a high-affinity interaction is characterized by a low KD 
value, the rapid recognition and binding of the interactants 
(high ka value), and the stability of the complex formation 
(low kd value). The niclosamide had lower ka and kd values 
comparable to that of wild type Axin peptide, indicating 
that niclosamide has efficient recognition and a slower 
rate of dissociation, and thus form stable complexes with 
GSK3 (Table 1). This SPR analysis result was consistent 
with the observation from AFF assay that niclosamide 
disrupts Axin-GSK3 interaction and blocks Axin function 
by competitive binding to GSK3. To further investigate 
the interaction of niclosamide on the Axin-binding 
site of GSK3 structurally, a molecular docking study 
was performed. The 1-chloro-3-nitrobezene group of 
niclosamide docks into a hydrophobic cavity formed by 
residues Val 263, Leu 266, Val 267, and Ile 270 of human 
GSK3β and is stacked onto residue Phe 293 through π–π 
interactions (Figure 3D). Niclosamide additionally forms 
hydrogen bonds with Pro294, Thr275, and Val 263, and 
halogen bonds with Tyr288 on the Axin-GSK3 interaction 
surface [24, 25]. These results indicate that niclosamide 
disrupts the Axin-GSK3 complex by inhibiting protein-
protein interactions (PPI).
To determine on-target effects of niclosamide 
on cells, we next made Axin2 knockdown cells using a 
doxycycline-inducible system. Evaluating the cytotoxic 
effects of niclosamide, we found the cell viability was 
largely increased at μM levels by inducible Axin2 
knockdown in HCT116 and SW480 cells (Figure 4A). 
Examining protein abundance of Snail and E-cadherin, 
the effects of niclosamide were largely abolished by 
Axin2 knockdown (Figure 4B). Further, canonical Wnt 
transcriptional activity, Axin2 transcript abundance, and 
E-cadherin reporter activity were minimally changed by 
niclosamide treatment in Axin2 knockdown colon cancer 
cells (Figure 4C), indicating that Axin2 is required for 
mode of action (MoA) of niclosamide on colon cancer 
cells. Therefore, niclosamide suppresses canonical Wnt 
activity and the Snail-mediated EMT program in an 
on-target manner by inhibiting Axin-GSK3 interaction 
(Figure 4D).
Previously, we have reported that Helicobacter 
pylori CagA binds to GSK3, resulting in depletion 
of GSK3 activity similarly to Axin and subsequent 
potentiation of Snail-mediated EMT [6]. To determine 
whether niclosamide can inhibit CagA binding to 
GSK3, we then transfected CagA expression vector and 
performed immunoprecipitation and immunoblot assay 
with niclosamide. Intriguingly, niclosamide also inhibited 
CagA-GSK3 interactions in cell lysates (Supplementary 
Figure 3D), and niclosamide treatment attenuated Snail 
Figure 2: Niclosamide increased nuclear GSK3 activity resulting in decreased nuclear β-catenin and Snail abundance. 
The colon cancer cells were treated with 0.25 μM niclosamide for 24 h, and the protein abundance of β-catenin and Snail in nuclear-
cytosolic fraction was determined by immunoblot analysis. HDAC1 and tubulin served as the loading control for nuclear and cytosolic 
fractions, respectively.
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Figure 3: Niclosamide directly interacts with GSK3, inhibiting Axin binding. (A) The 293 cells were transfected with His-
tagged Axin2 expression vector and treated with increasing doses of niclosamide for an 8 h period. The GSK3 binding activities in lysate 
were determined by Ni-NTA bead immunoprecipitation followed by immunoblot analysis for GSK3. (B) Recombinant His-tagged GSK3 
was subjected to immunoprecipitation to determine FITC-conjugated Axin peptide (19 mer) binding. Remaining fluorescent intensities 
following incubation with different doses of niclosamide are presented from triplicate experiments. (C) Surface plasmon resonance (SPR) 
sensograms showing the interaction of niclosamide with immobilized GSK3 (left panel). Five different niclosamide concentrations were 
analyzed (0 - 100μM). Response units at equilibrium are plotted against the concentration of niclosamide (right panel). The data were 
analyzed using the ProteOn Manager Software 2.0. (D) Predicted binding mode of niclosamide on the Axin-binding site of GSK3 shown 
as surface model (left panel). Superimposition of the Axin peptide and niclosamide to demonstrate their similar binding modes within the 
peptide binding site of GSK3 (top right panel). Detailed interactions between niclosamide and GSK3 are shown as stick model H-bonds 
are indicated by red dashed lines (bottom right panel). GSK3, Axin peptide, and niclosamide are colored in yellow, cyan, and green, 
respectively. Figures were drawn using PyMol (Delano Scientific LLC, San Carlos, CA).
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protein abundance that is stabilized by CagA in a dose-
dependent manner (Supplementary Figure 3E). These data 
further support that niclosamide inhibits binding of H. 
CagA as well as of Axin onto GSK3, resulting in reversion 
of Snail-mediated EMT.
Niclosamide reverts the Snail-mediated EMT 
program in vivo
The Wnt activation and Snail-mediated EMT 
promote cell migration and tumorigenic potential along 
with increased therapeutic resistance. When we treated 
the niclosamide at nM level, the migration potential of 
colon cancer cells was significantly inhibited (Figure 5A). 
Conversely, when Axin and Snail levels were increased 
with tankyrase inhibitor XAV939, cell migratory potential 
significantly increased (Supplementary Figure 4) [9, 26], 
supporting that Axin2 serves tumor progression in colon 
cancer cells. Further, niclosamide treatment sensitized 
cytotoxic effect of 5-fluorouracil (5-FU) in colon cancer 
cells compared to control (Figure 5B). Next, we examined 
the effect of niclosamide on in vivo tumorigenic potentials 
in HCT116 and SW480 cells. Consistent with previous 
observations [12, 13], intraperitoneal administration of 
niclosamide significantly suppressed in vivo tumor growth 
of colon cancer cells (Figure 5C). For further evaluation 
of the in vivo MoA of the niclosamide suppressing Snail-
mediated EMT, tumor xenograft tissues were collected 
3 days after treatment of vehicle or niclosamide (50 and 
200 mg per kg, body weight), and the protein abundance 
of Snail and E-cadherin in tumor extracts were analyzed. 
Indeed, Snail abundance in in vivo samples was decreased 
whereas E-cadherin abundance was increased by 
niclosamide treatment in a dose-dependent manner (Figure 
5D). These results indicate that niclosamide suppresses 
tumorigenic potential in vivo by reverting Snail-mediated 
EMT.
Oral administration of niclosamide suppresses 
adenoma formation in APC-MIN mice
The adenomatous polyposis coli (APC), most 
commonly mutated in sporadic colon cancer, is a key 
tumor suppressor gene that acts as a gatekeeper of 
intestinal epithelial homeostasis by restricting cytosolic 
β-catenin [27-30]. Mutational inactivation of APC is 
also a well-known genetic background of FAP patients. 
Axin2, a representative downstream target of TCF/
LEF transcriptional machinery, is highly abundant in 
colon cancer cells as well as in adenomas due to loss 
of APC function [18, 19, 21]. Given the observations 
that niclosamide suppresses canonical Wnt activity and 
EMT via Axin-GSK3 inhibition, we next tested whether 
niclosamide could attenuate TCF/LEF transcriptional 
activity and Snail abundance induced by mutant APC. 
When we transfected mutant APC in 293 cells, TCF/
LEF transcriptional activity increased and niclosamide 
treatment relieved this activity together with decreased 
ß-catenin and Snail abundance in a dose-dependent 
manner (Figure 6A), indicating that niclosamide 
effectively attenuates canonical Wnt activity and Snail 
abundance induced by APC mutation. To prove functional 
relevance in vivo, we preliminarily tested the effect of 
niclosamide on adenoma formation in APC-MIN (multiple 
intestinal neoplasia, APCΔ850) mice model. APC-MIN 
mice (3 weeks old) were intraperitoneally injected with 
daily doses of vehicle as control (n = 6, 6 times/week) 
or 50 mg/kg niclosamide (n = 7, 6 times/week). Fourteen 
weeks after niclosamide administration, the intestinal 
adenoma burden was significantly decreased while the 
body weight was unaffected (Supplementary Figure 5A). 
FAP having an inherited APC germ-line mutation results 
in multiple adenomatous polyps and a nearly 100% risk 
of colon cancer before age 40 [31, 32]. While several 
adjunctive therapies with COX or ornithine decarboxylase 
inhibitors have been approved in patients with FAP, 
long-term follow up results were limited on adenoma 
formation, with increased risk of various complications, 
such as cardiovascular events [33, 34]. Upregulation of 
Axin2 and Snail abundance in APC-MIN adenoma or 
precancerous sporadic adenoma has been well-reported 
[18, 35], and Snail inhibition using anti-sense morpholino 
suppressed adenoma formation in APC-MIN model [36]. 
To examine the clinical relevance of our observations, we 
next designed in vivo experiments to test the therapeutic 
availability of niclosamide for FAP patients. APC-MIN 
mice were orally administrated 6 times/week with daily 
doses of vehicle (15% sugar gel) as control (n = 8) or 50 
mg/kg niclosamide (n = 10) or 200 mg/kg niclosamide (n 
= 10). Interestingly, oral administration of niclosamide 
for 14 weeks end-point significantly suppresses intestinal 
adenoma formation in APC-MIN model, with no apparent 
dose-dependency (Figure 6B and Supplementary Figure 
5B). The mice were stable during the drug treatment. 
Table 1: Affinity and kinetic data for GSK3 interactions determined by SPR analysis.
Compound ka, M-1sec-1 kd, sec-1 KD, μM
Niclosamide 1.24E+04 4.26E-01 3.45E-05
Axin peptide 8.25E+04 9.83E+01 1.19E-05
The association rate (ka), dissociation rate (kd) and equilibrium dissociation constant (KD) of each virtual hit are shown in the 
table. KDvalues were calculated by the individual ka and kd values.
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Figure 4: On-target effects of niclosamide in colon cancer cells. (A) Cell viability of colon cancer cells after niclosamide treatment 
were measured following inducible knockdown of Axin2 (Dox +). (B) Niclosamide regulates EMT genes in an Axin2-dependent manner. 
The colon cancer cells expressing inducible shRNA for Axin2 (Dox+) were treated with niclosamide (0.25 μM), and indicated protein 
abundance was determined by immunoblot analysis. (C) The TCF/LEF reporter activity (left panel), Axin2 transcript abundance (middle 
panel), and E-cadherin reporter activity (right panel) in colon cancer cells expressing inducible knockdown of Axin2 were determined 
under niclosamide treatment (0.25 μM). (D) Schematic diagram of mechanism of action of niclosamide. In the absence of niclosamide, the 
Axin2 binds to GSK-3, resulting in up-regulation of Snail-mediated EMT and canonical Wnt activity (left panel). Disruption of Axin-GSK3 
interaction by niclosamide allows degradation of Snail and attenuation of canonical Wnt activity (right panel).
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Figure 5: Niclosamide suppresses tumorigenic potential and EMT in vivo. (A) The migratory activity of colon cancer cells 
treated with various concentrations of niclosamide was determined by transwell migration assay (left panels). Statistical significances 
compared to control (right panel) are denoted as **, P < 0.01 by a two-tailed Student’s t-test. (B) Combination effect of niclosamide 
and 5-FU on HCT116 and SW480 cells. The colon cancer cells were treated with various concentrations of 5-FU and niclosamide as 
indicated. Cell viability was measured trypan blue exclusion assay after 48 h of incubation. **, P < 0.01 by a two-tailed Student’s t-test. 
(C) Niclosamide inhibits the growth of colon cancer cells in vivo. HCT116 and SW480 colon cancer cells were inoculated into the flank 
of athymic nude mice prior to 24 h of treatment. Niclosamide (50 mg/kg dissolved in Cremophor EL) was intraperitoneally administered. 
Two asterisks, P < 0.01 compared to the vehicle control by Mann-Whitney test. (D) Niclosamide treatment reversed Snail-mediated EMT 
in SW480 xenografts. Tumor-bearing nude mice were given 50 mg/kg or 200 mg/kg body weight niclosamide for 3 days prior to sacrifice. 
Tumor tissues were collected and the protein abundances of Snail and E-cadherin in tumor lysates were then measured using immunoblot 
assay (left panels). The band intensity on each blot was normalized to the loading control and the relative protein abundance is shown as 
the ratio to that in the vehicle control (middle and right panels). Results are shown as means and s.d. One asterisk, P < 0.01; Two asterisks, 
P < 0.001 compared to the vehicle control by Mann-Whitney test.
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These results suggest the prospect of niclosamide as a 
repositioned drug for FAP patients.
DISCUSSION
Niclosamide (trade name Niclocide in US) is an 
orally available drug having antihelmintic and potentially 
antineoplastic activity. Due to its effectiveness and low 
cost, WHO has designated niclosamide as an essential 
medication in a basic health plan. Although its molecular 
target was not clearly identified, recent evidence suggests 
niclosamide may function as an anticancer drug by 
regulating many signaling pathways, such as Wnt, 
S100A4, Notch, and androgen receptor [12-14]. In this 
study, we provide evidence that niclosamide inhibits Axin 
binding to GSK3, resulting in attenuation of canonical 
Figure 6: Niclosamide attenuates Wnt activity induced by mutant APC. (A) Niclosamide suppressed TCF/LEF transcriptional 
activities induced by mutant APC in a dose-dependent manner. The 293 cells were transiently transfected with mutant APC (1-1309 or 
1-1941) and Topflash reporter vector. Cells were treated with increasing concentrations of niclosamide (0, 0.125, 0.25, and 0.5 μM) for 
24 h. TCF/LEF transcriptional activities were quantified by measuring relative luciferase activity normalized to Renilla (left panel). The 
lysates of reporter assay were subjected to immunoblot assay for β-catenin and Snail (right panels). (B) Schematic diagram of experimental 
design for oral administration into APC-Min mice model (upper). Body weight (left), total number of polyps (middle), and size distribution 
of polyps (right) in small intestine (small, < 1 mm; medium 1~3 mm; large > 3 mm). Results are shown as means and s.d. One asterisk, P 
< 0.01; Two asterisks, P < 0.001 compared to the vehicle control by Mann-Whitney test.
Oncotarget31851www.impactjournals.com/oncotarget
Wnt activity and reversion of the Snail-mediated EMT 
program in colon cancer cells. We also provide clinical 
relevance of niclosamide as a potential therapeutics for 
FAP patients.
Recent observation suggests that many canonical 
Wnt target genes play an important role in EMT of colon 
cancer and are involved in crosstalk with metastatic 
potential [37]. Thus, understanding the key regulatory 
networks and functional mediators of the EMT program 
provides the opportunity to develop a novel therapeutic 
strategy. In this study, we focused on regulation of 
Snail-mediated EMT with small molecule niclosamide, 
which disrupts the Axin-GSK3 complex involved in 
canonical Wnt signaling. Our observations provide 
several functional and clinical insights relevant to cancer 
therapeutics involving reversion of the Snail-mediated 
EMT program.
First, we identified GSK3-Axin2 interaction as a 
molecular target of niclosamide, providing a novel MoA to 
suppress canonical Wnt activity through reversion of the 
Snail-mediated EMT program in cancer cells. Although it 
is hard to prove the existence of an off-target effect, our in 
vitro and in vivo evidence support that niclosamide exerts 
a biological effect by disrupting the Axin-GSK3 complex, 
at least in part. Secondly, aberrant activation of the Wnt 
pathway is associated with a variety of diseases, including 
cancer, bone metabolism, degenerative diseases, and 
fibrosis [38]. Despite the many proposed Wnt therapeutic 
targets, such as Frizzled receptor, Porcupine, Dishevelled, 
p300, and CBP (CREB-binding protein), effective 
molecular targets for regulating the canonical Wnt pathway 
remain limited [38]. During the Wnt activation, the APC-
Axin-Dishevelled scaffolding complex is a key regulator 
of TCF/LEF activity. We found Axin2-GSK3 interaction to 
be a novel target for attenuating canonical Wnt activity and 
subsequent reversion of the Snail-mediated EMT program. 
Based on the structure of the protein-protein interaction 
(PPI) [24, 39], development of a new small molecule that 
specifically inhibits Axin-GSK3 PPI holds potential as a 
new cancer therapeutic. Third, we have previously shown 
that the Snail-mediated EMT program is tightly controlled 
by the canonical Wnt pathway and the p53 tumor 
suppressor [4, 5]. Based on experimental evidence with 
salinomycin [2], several EMT targets (mainly involving 
TGF-β signaling) for pharmacologic agents have been 
proposed [40]. In this study, we provide experimental 
evidence that the Snail-mediated EMT program closely 
coupled with the canonical Wnt pathway constitutes a 
promising nexus for human cancer therapeutics. Lastly, 
germ-line defects in APC cause FAP, in which affected 
patients develop hundreds of adenomatous polyps 
at an early age and ultimately progress to colorectal 
adenocarcinoma with 100% penetrance [31, 32]. While 
the US FDA and European Medicines Agency approved 
several anti-inflammatory drugs as adjunct treatments 
[32], targeted therapeutics for the Wnt pathway are still 
limited. We showed that orally administered niclosamide 
can be effectively repositioned drug for FAP. While a 
dose-dependent regression of adenomas was not found, 
probably due to the daily administration design, the 
efficacy in APC-MIN mice reported in the present study 
strongly supports the clinical relevance of niclosamide for 
FAP. Further studies of dosage and long-term toxicity are 
needed to confirm its therapeutic potential and clinical 
benefit for FAP patients.
MATERIALS AND METHODS
Cell lines and reagents
Colon cancer cell lines (HCT116, SW480 and 
DLD1) and 293 cells from ATCC were maintained under 
conditions recommended by the provider. Niclosamide 
(Cayman), tankyrase inhibitor XAV939 (X3004, Sigma), 
and 5-flulorouracil (Sigma) were solubilized in DMSO for 
in vitro experiments. E-cadherin reporter gene construct 
and Topflash reporter having 8x TCF/LEF binding sites 
were used as described previously [4, 7, 8]. The Tet-
pLKO-puro vector (#21915 obtained from Addgene) 
was used for inducible shRNA knockdown. The target 
sequence of shRNA for Axin2 was 5’-accaccactacatccacca. 
Flag-tagged Helicobacter pyroli CagA, HA-tagged 
GSK3β, His-tagged Axin2, and Snail expression vector 
were described previously [6]. Mutant APC expression 
vectors pCMV-neo-Bam APC 1-1309 (#16508) and 
pCMV-neo-Bam APC 1-1941 (#16510) were obtained 
from Addgene.
Cell viability, cell migration
For cell viability assay, 1 × 105 cells were plated 
into 6-well plates with normal culture medium one day 
before niclosamide treatment. The cells were washed 
with PBS and cultured in culture medium for 48 h with 
niclosamide or in combination with 5-FU. Cell death was 
measured by trypan blue exclusion assay and cell viability 
was calculated with the equation [1 - (cell death/total) × 
100]. For migration assays with niclosamide, colon cancer 
cells (5 × 104) were seeded into transwell inserts (5.0 μm 
pore, BD Biosciences). After a 48 h culture period with or 
without niclosamide as indicated in the Figures, the upper 
side of the membrane was rubbed with cotton swab and 
the numbers of cells migrating to the basal side insert were 
stained with 0.25% crystal violet and counted. Cell counts 
were determined in five random fields.
Reporter assay, immunoblot assay, 
immunoprecipitation
Colon cancer cells were transfected with 100 ng of 
reporter gene constructs and 1 ng of transfection control 
pRL-SV40-Renilla. Reporter activities were measured 
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with a dual luciferase assay system (Promega) 48 h after 
transfection and normalized by measuring co-transfected 
renilla activity. Reporter gene activities are presented as 
light units relative to those obtained from negative control. 
For the western blot analyses, protein extracts were 
prepared in Triton X-100 lysis buffer. Antibodies against 
Snail (3895s, Cell Signaling, 1:2,000), GSK3β (ab82542, 
Abcam, 1:1,000), E-cadherin (#610181, BD Transduction, 
1:5,000), β-catenin (#610154, BD Transduction, 1:5,000), 
APC (#2504, Cell Signaling, 1:1,000), LRP-6 (C5C7, 
Cell Signaling, 1:1,000), pLRP-6 (S1490, Cell Signaling, 
1:1,000), and alpha-Tubulin (LF-PA0146A, Ab Frontier, 
1:5,000) were obtained from the commercial vendors. 
For immunoprecipitation assay for Axin2, doxycycline-
inducible His-tagged Axin2 expression vector were stably 
transfected into MCF-7 cells as described previously 
[8]. Whole cell Triton X-100 lysates were incubated 
with Ni-NTA beads (Invitrogen) with different doses of 
niclosamide. The recovered proteins were resolved by SDS-
PAGE and subjected to immunoblot analysis for GSK3 and 
input (1/20 volume) control. The protein abundances of 
Snail and GSK3 were determined from nuclear-cytosolic 
fractionation of protein lysates with hypotonic buffer as 
described previously [4, 8]. Briefly, the colon cancer cells (1 
× 106) were collected into microcentrifuge tubes. The PBS-
washed cells were treated with 400 μl of hypotonic buffer 
(10 mM HEPES, pH7.9; 10 mM KCl; 1 mM DTT with 
protease inhibitors) on ice for 5 min. The cell membrane 
was ruptured by adding 10% NP-40 to a final concentration 
of 0.6%, then vigorously vortexed for 10 sec followed by 
high-speed centrifuge for 30 sec. The supernatant cytosolic 
fractions were collected separately, and nuclear pellets 
were washed with ice-cold PBS twice. Nuclear protein was 
extracted with hypertonic buffer (20 mM HEPES, pH7.9; 
0.4 M NaCl; 1mM DTT with protease inhibitors) for 15 
min on ice followed by high-speed centrifuge.
Cell-free Axin-FITC fluorescence (AFF) assay
His-tagged recombinant GSK3β was obtained 
from sf9 insect cells as described previously.[6] The 
FITC-conjugated 19-mer Axin peptide (Axin1, 383-401, 
VEPQKFAEELIHRLEAVQR), which is reported to 
bind GSK3 as an amphipathic α-helix, was chemically 
synthesized (Peptron)[24]. His-tagged recombinant 
GSK3 (300ng) was immobilized to Ni-NTA beads 
followed by phosphate buffed saline (PBS, pH 7.4) 3 
times. The synthetic Axin peptide (10 ng) with different 
concentrations of niclosamide was subjected to the 
beads with His-tagged recombinant GSK-3 to examine 
competitive binding of Axin peptide for 2 h at 4 oC. After 
PBS washing 3 times, the Ni-NTA beads were subjected 
to quantitative fluorescent measurement at an excitation 
wavelength of 488 nm and an emission wavelength of 525 
nm. The fluorescent intensities are presented as relative 
fluorescence intensity to that obtained from negative 
control from triplicate experiments.
Surface plasmon resonance (SPR) Analysis
SPR was conducted using the ProteOnTM 
XPR36 Protein Interaction Array system (Bio-Rad 
Laboratories, Inc., CA, USA). Purified recombinant 
GSK3β was immobilized on the ProteOn GLH sensor 
chip. Niclosamide or 19-mer wild type Axin peptide or 
mutant peptide (VEPQKAAEEAIHRAEAVQR, mutation 
underlined) were diluted by phosphate-buffered saline 
with Tween 20 and 1% DMSO at different concentrations 
and then flowed over the chip at a rate of 100 μl/min. Data 
were analyzed with the ProteOn Manager Software 2.0 
using the standard Langmuir models for fitting kinetic 
data. The rate of complex formation is represented by 
the association constant (ka, in the unit of M
-1s-1) and the 
rate of complex decay is represented by the dissociation 
constant (kd, in the unit of s
-1), as given by Equation 1:




A high-affinity interaction is characterized by a low 
dissociation constant (KD), rapid recognition and binding 
of the interactants (rapid “on rate,” or high ka), and the 
stability of complex formation (slow “off rate,” or low kd) 
as shown in the equation, KD = kd/ka.
Molecular docking study
Molecular docking calculations were performed 
using the Maestro 10.4 molecular docking suite. The 
crystal structure of the human (pTyr216)-GSK3β bound 
with an Axin peptide was obtained from the RCSB Protein 
Data Bank (PDB ID: 3ZDI). All water molecules and 
metal ions were removed, and hydrogen atoms were added 
to the protein. To sample different ligand protonation 
states at physiological pH, the Epik module was used. 
All compounds were energy-minimized using LigPrep 
and then docked to receptor structures using the standard 
precision (SP) module of the Glide docking module within 
the Schrödinger Suite. Prior to Glide docking studies, a 
receptor grid box was generated at the centroid of the 
co-crystallized ligands. Post-minimization was used to 
optimize the geometry of the poses.
Microarray data analysis of NCI-60 cancer cell 
panel and quantitative RT-PCR
Publicly available gene expression profiling 
data from 9 different cancer tissues of NCI-60 panel 
(GSE29288), using Agilent-014850 Whole Genome 
Microarray 4x44k G4112F, were downloaded from the 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/). The data set consists of 132 samples (12 breast, 
12 central nervous system, 18 colon, 18 leukemia, 14 
melanoma, 22 non-small cell lung, 14 ovarian, 4 prostate, 
18 renal cell cancer cells). The data were normalized 
with the voom transformation after trimmed mean of 
M-values (TMM) as implemented in the R Bioconductor 
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“limma” and “edgeR” packages. For visualizing the Axin2 
expression value of 3 probes (A-24_P298027, A_23_
P159395, and A-23_P148015), heatmap2 as implemented 
in the R Bioconductor “gplots” package was used. Total 
RNA was isolated using TRIzol reagent (Invitrogen) 
following the manufacturer’s protocol. The SuperScript 
III synthesis kit (Invitrogen) was used to generate cDNA. 
Real-time quantitative PCR (qPCR) analysis for Axin2 
transcript was performed with an ABI-7300 instrument 
under standard conditions and SBGR mix (n = 3). The 
expression of ΔCt value from each sample was calculated 
by normalizing with GAPDH. The primer sequences were 
5'-AAGGGCCAGGTCACCAAAC-3' for Axin2 forward, 
5'-CCCCCAACCCATCTTCGT-3' for Axin2 reverse, 
5’- ATGGGTGTGAACCATGAGAAG-3’ for GAPDH 
forward, and 5’- AGTTGTCATGGATGACCTTGG-3’ for 
GAPDH reverse.
In vivo assay and APC-MIN mice experiment
All animal experiments were performed in 
accordance with the Institutional Animal Care and Use 
Committee of Yonsei University and approved by the 
Animal Care Committee of the Yonsei University College 
of Dentistry and National Cancer Center Research 
Institute. Female athymic nude mice (6 weeks old) were 
used for xenograft assays. HCT116 (5 × 106) and SW480 
(5 × 106) cells were resuspended in 100 μl of PBS and 
injected into flank subcutaneous tissue. The mice were 
randomly assigned to two groups and treated 24 h after 
transplantation intraperitoneally daily with vehicle 
or niclosamide in vehicle. For in vivo intraperitoneal 
application, niclosamide was dissolved in 10% Cremophor 
EL (BASF) and 0.9% NaCl. After colon cancer cell 
inoculation, mice were monitored daily and weighed twice 
weekly, then measured with calipers when the tumors 
became visible. Tumor volume was calculated with the 
equation (LXW2)/2, where L is the longer dimension of the 
tumor and W is the shorter dimension. APCMin mice were 
produced by mating wild type C57BL/6J female mice with 
APCMIN+ male mice (Jackson laboratory strain 002020). 
APCMin progeny were identified by a polymerase chain 
reaction-based assay and randomly assigned to subgroups 
at 3 weeks of age. For intraperitoneal administration, 
vehicle or niclosamide in vehicle (50 mg/kg) were injected 
daily (6 days/week), and the mice were monitored daily 
and weighed twice weekly. After 14 weeks end-point, the 
mice were sacrificed and entire intestines were removed. 
The intestinal segments were opened longitudinally with 
scissors, rinsed in saline, and then spread out individually. 
Tissue were fixed with 10% buffered formalin 24 h and 
then washed twice with 70% ethanol. Intestinal segments 
were examined using stereomicroscope. The number of 
adenoma (small, < 1 mm; medium 1~3 mm; large > 3 mm) 
was counted from each mouse. For oral administration, 
the APC-MIN mice were fed niclosamide mixed with 
15% sugar gel vehicle daily (6 days/week) for 14 weeks. 
The number and size of adenomas were counted under 
stereomicroscope.
EMT in tumor xenografts
Nude mice were subcutaneously inoculated with 
SW480 cells (5 × 106) cells. When the tumors reached 
an average of 500 mm3, mice were randomized into three 
groups and given intraperitoneal injections of a vehicle or 
niclosamide in vehicle (50 mg/kg, 200 mg/kg) for 3 days 
prior to sacrifice. Tissue lysate was isolated using Pro-prep 
protein extraction solution (#17081, Intron) from tumor 
cryosections. Protein abundance of Snail and E-cadherin 
in tumor samples was detected by immunoblot assay.
Statistics
All statistical analysis of cell viability, AFF assay, 
cell migration, and reporter assay was performed with 
two-tailed Student’s t-tests; data are expressed as means 
and s.d.The double asterisks denote P < 0.01, one asterisk 
denoting P < 0.05. Statistical significance of animal 
experiments was determined using the Mann-Whitney 
test; data are expressed as mean and s.e.m. for tumor 
volume. No statistical method was used to predetermine 
sample size.
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